| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_UBAP2_0023100 | Intron-Exon-Intron | chr9:34017048-34024312 | chr9:34017050-34024314 | 250 nt | 0.4200 |
| hsa_UBAP2_0023300 | Intron-Exon-Intron | chr9:34017048-34025481 | chr9:34017050-34025483 | 223 nt | 0.3991 |
| hsa_UBAP2_0023200 | Intron-Exon-Intron | chr9:34017048-34032910 | chr9:34017050-34032912 | 250 nt | 0.4240 |
| hsa_UBAP2_0023400 | Intron-Intron | chr9:34020246-34020410 | chr9:34020248-34020412 | 165 nt | 0.4545 |
| hsa_chr9_0416600 | Intergenic-Intergenic | chr9:34022691-34024143 | chr9:34022693-34024145 | 1453 nt | 0.4198 |
| hsa_UBAP2_0023500 | Intron-Intron | chr9:34022924-34023291 | chr9:34022926-34023293 | 368 nt | 0.4891 |
| hsa_chr9_0416700 | Intergenic-Intergenic | chr9:34026354-34026561 | chr9:34026356-34026563 | 208 nt | 0.3750 |
| hsa_UBAP2_0023600 | Intron-Intron | chr9:34029613-34029859 | chr9:34029615-34029861 | 247 nt | 0.4980 |
| hsa_chr9_0416800 | Intergenic-Intergenic | chr9:34031049-34031540 | chr9:34031051-34031542 | 492 nt | 0.4980 |
| hsa_UBAP2_0023700 | Intron-Intron | chr9:34034023-34044644 | chr9:34034025-34044646 | 250 nt | 0.3440 |
A review of literature indicates that the circUBAP2 is an oncogenic circular RNA upregulated in osteosarcoma patient samples, where its high expression is correlated with lower overall survival and promotes tumor growth while inhibiting apoptosis [Di Agostino et al. DOI:10.3389/fcell.2020.00389]. A study in human patients with heart failure after acute myocardial infarction demonstrated that the expression level of the circUBAP2 was not significantly different between patients with sacubitril/valsartan resistance and non-resistant patients in quantitative real-time PCR validation [Su et al. DOI:10.1016/j.ejphar.2023.175547].